Entrada Therapeutics (TRDA) Net Income (2020 - 2026)

Entrada Therapeutics has reported Net Income for 7 years, with the latest figure at -$39.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income fell 128.93% year-over-year to -$39.7 million; the trailing twelve-month figure through Mar 2026 stood at -$166.2 million (down 772.7% YoY), and the FY2025 full-year result was -$143.8 million, down 319.18% from the prior year.
• Net Income for Q1 2026 stood at -$39.7 million, down from -$39.2 million in the prior quarter.
• The five-year high for Net Income was $55.0 million in Q2 2024, with the low at -$44.2 million in Q3 2025.
• Average Net Income over 5 years is -$12.9 million, with a median of -$21.7 million recorded in 2022.
• Year-over-year, Net Income soared 452.05% in 2024 and tumbled 3794.25% in 2025.
• Tracing TRDA's Net Income over 5 years: stood at -$24.6 million in 2022, then soared by 61.59% to -$9.5 million in 2023, then jumped by 111.22% to $1.1 million in 2024, then plunged by 3794.25% to -$39.2 million in 2025, then dropped by 1.33% to -$39.7 million in 2026.
• The last three Net Income figures came in at -$39.7 million (Q1 2026), -$39.2 million (Q4 2025), and -$44.2 million (Q3 2025), per Business Quant data.

Peer Comparison